Drug (ID: DG00328) and It's Reported Resistant Information
Name
Ceftolozane sulfate
Synonyms
Ceftolozane; CXA-101; CXA-301; CXA-301); Cephalosporin derivatives, Astellas; Cephalosporinderivatives, Calixa Therapeutics; FR-193879; FR-264205; FR-295389; CXA-101 (inhaled), Calixa; CXA-101 (inhaled), Cubist; Cephalosporin derivative (H pylori/P aeruginosa infection), Astellas; CXA-101 (inhaled, bacterial lung infection), Cubist
    Click to Show/Hide
Indication
In total 1 Indication(s)
Respiratory infection [ICD-11: CA07-CA4Z]
Phase 4
[1]
Structure
Drug Resistance Disease(s)
Disease(s) with Clinically Reported Resistance for This Drug (2 diseases)
Bacterial infection [ICD-11: 1A00-1C4Z]
[2]
Malaria [ICD-11: 1F45]
[1]
Target Bacterial Penicillin binding protein (Bact PBP) NOUNIPROTAC [1]
Click to Show/Hide the Molecular Information and External Link(s) of This Drug
Formula
C23H32N12O12S3
IsoSMILES
CC(C)(C(=O)O)O/N=C(\\C1=NSC(=N1)N)/C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C[N+]4=CC(=C(N4C)N)NC(=O)NCCN)C(=O)O.OS(=O)(=O)[O-]
InChI
1S/C23H30N12O8S2.H2O4S/c1-23(2,20(40)41)43-31-11(15-30-21(26)45-32-15)16(36)29-12-17(37)35-13(19(38)39)9(8-44-18(12)35)6-34-7-10(14(25)33(34)3)28-22(42)27-5-4-24;1-5(2,3)4/h7,12,18,25H,4-6,8,24H2,1-3H3,(H7,26,27,28,29,30,32,36,38,39,40,41,42);(H2,1,2,3,4)/b31-11+;/t12-,18-;/m1./s1
InChIKey
UJDQGRLTPBVSFN-GZGOMJRCSA-N
PubChem CID
11592969
TTD Drug ID
D03IUD
DrugBank ID
DB09050
Type(s) of Resistant Mechanism of This Drug
  DISM: Drug Inactivation by Structure Modification
Drug Resistance Data Categorized by Their Corresponding Diseases
ICD-01: Infectious/parasitic diseases
Click to Show/Hide the Resistance Disease of This Class
Bacterial infection [ICD-11: 1A00-1C4Z]
Click to Show/Hide
Drug Resistance Data Categorized by Their Corresponding Mechanisms
       Drug Inactivation by Structure Modification (DISM) Click to Show/Hide
Key Molecule: Beta-lactamase (BLA) [2]
Molecule Alteration Missense mutation
p.Y221H
Resistant Disease Bacterial infection [ICD-11: 1A00-1C4Z]
Experimental Note Identified from the Human Clinical Data
In Vitro Model Escherichia coli TOP10 83333
Escherichia coli EC13 562
Experiment for
Molecule Alteration
Whole genome sequencing assay
Experiment for
Drug Resistance
Disk diffusion test assay
Mechanism Description The CMY-136 Beta-lactamase, a Y221H point mutant derivative of CMY-2,confers an increased level of resistance to ticarcillin, cefuroxime, cefotaxime, and ceftolozane/tazobactam.
Malaria [ICD-11: 1F45]
Click to Show/Hide
Drug Resistance Data Categorized by Their Corresponding Mechanisms
       Drug Inactivation by Structure Modification (DISM) Click to Show/Hide
Key Molecule: CAM-1 carbapenemase (CAM1) [1]
Molecule Alteration Expression
Up-regulation
Resistant Disease Pseudomonas infection [ICD-11: 1F45.1]
Experimental Note Identified from the Human Clinical Data
In Vitro Model Escherichia coli TOP10 83333
Pseudomonas aeruginosa N17-01167 287
Pseudomonas aeruginosa N17-01173 287
Pseudomonas aeruginosa N17-02436 287
Pseudomonas aeruginosa N17-02437 287
Experiment for
Molecule Alteration
Whole genome sequencing assay
Experiment for
Drug Resistance
Vitek 2 assay; Etest assay
Mechanism Description A novel class B Beta-lactamase gene, blaCAM-1, exhibited resistance to imipenem, meropenem, doripenem, cefotaxime, ceftazidime, cefoxitin, piperacillin/tazobactam, ceftazidime/avibactam and ceftolozane/tazobactam.
References
Ref 1 Identification of a novel metallo-Beta-lactamase, CAM-1, in clinical Pseudomonas aeruginosa isolates from Canada. J Antimicrob Chemother. 2019 Jun 1;74(6):1563-1567. doi: 10.1093/jac/dkz066.
Ref 2 Genetic, Biochemical, and Structural Characterization of CMY-136 Beta-Lactamase, a Peculiar CMY-2 Variant. ACS Infect Dis. 2019 Apr 12;5(4):528-538. doi: 10.1021/acsinfecdis.8b00240. Epub 2019 Mar 7.

If you find any error in data or bug in web service, please kindly report it to Dr. Sun and Dr. Zhang.